Prophylactic treatment of pediatric migraine: Is there anything new in the last decade?

Research output: Contribution to journalArticlepeer-review


Migraine is a frequent and very disabling disease, especially at pediatric age. Despite this, there are few controlled data on the prophylactic treatment of primary headaches in this category of age. Given that the recently introduced calcitonin gene-related peptide (CGRP) inhibitors (CGRP-r) are still limited to adulthood, there is no drug with exclusive indication for migraine treatment in pediatric age. This raises several limitations in terms of adherence and effectiveness of the therapy. Moreover, the scenario is complicated by placebo response, which is larger in children and adolescents than in adults and often leads to an improvement in the attack frequency even in absence of any active pharmacological treatment. Our aim was to investigate the real evidence concerning the prophylactic therapy of pediatric migraine by reviewing the clinical studies published between 2010 and 2019.

Original languageEnglish
Article number771
JournalFrontiers in Neurology
Issue numberJUL
Publication statusPublished - Jan 1 2019


  • Guidelines
  • Migraine
  • Pediatric migraine
  • Preventive
  • Prophylactic drugs
  • Therapy
  • Treatment

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Prophylactic treatment of pediatric migraine: Is there anything new in the last decade?'. Together they form a unique fingerprint.

Cite this